Table 4. Occurrence of AOEs following... | American Society of Hematology

Table 4.

Occurrence of AOEs following prospective dose reduction in October 2013 in CP-CML patients with no prior AOEs as of 10 October 2013

	Occurrence of AOEs in patients with dose reduction after October 2013					Occurrence of AOEs in patients with no dose reduction after October 2013
	Total	45 to 30 mg/d	45 to 15 mg/d	30 to 15 mg/d	Other reduction	Total	45 mg/d	30 mg/d	15 mg/d
Denominator*	63	10	26	24	3	44	5	10	29
AOE, n (%)	12 (19)	1 (10)	4 (15)†	6 (25)†	1 (33)	8 (18)	1 (20)	1 (10)	6 (21)
No AOE, n (%)	51 (81)	9 (90)	22 (85)	18 (75)	2 (67)	36 (82)	4 (80)	9 (90)	23 (79)

	Occurrence of AOEs in patients with dose reduction after October 2013					Occurrence of AOEs in patients with no dose reduction after October 2013
	Total	45 to 30 mg/d	45 to 15 mg/d	30 to 15 mg/d	Other reduction	Total	45 mg/d	30 mg/d	15 mg/d
Denominator*	63	10	26	24	3	44	5	10	29
AOE, n (%)	12 (19)	1 (10)	4 (15)†	6 (25)†	1 (33)	8 (18)	1 (20)	1 (10)	6 (21)
No AOE, n (%)	51 (81)	9 (90)	22 (85)	18 (75)	2 (67)	36 (82)	4 (80)	9 (90)	23 (79)

Patients are classified according to the lowest dose received after October 2013.

Abbreviations are explained in Table 1 and Table 3.

Number of patients with no AOEs occurring before 10 October 2013.

See supplemental Table 2 for additional information.